MarketCap
Facebook
X
TelegramQuarterly report 2025-Q1
added 05-14-2025
Country |
 USA |
IPO year |
2020 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
51.8 M |
Market Cap[1] |
$ 207 M |
EBITDA (LTM) |
$ -86.6 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
-1.65 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
AbCellera Biologics
ABCL
|
$ 3.55 | -0.28 % | $ 1.06 B | Nasdaq Global Select Market |  Canada |
 |
Adagene
ADAG
|
$ 3.91 | -2.01 % | $ 220 M | Nasdaq Global Market |  China |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
 |
AC Immune SA
ACIU
|
$ 3.32 | 6.07 % | $ 229 M | Nasdaq Global Market |  Schweiz |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | China |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | Canada |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
ADC Therapeutics SA
ADCT
|
$ 4.11 | -2.61 % | $ 105 M | NYSE | Schweiz |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Aptorum Group Limited
APM
|
$ 0.79 | 0.04 % | $ 4.31 M | Nasdaq Global Select Market | China |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market |  Britain |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
argenx SE
ARGX
|
$ 706.03 | 0.39 % | $ 25 B | Nasdaq Global Select Market |  Niderland |
 |
Alterity Therapeutics Limited
ATHE
|
$ 3.34 | -7.48 % | $ 8.04 B | Nasdaq Capital Market |  Australia |
 |
Ascendis Pharma A/S
ASND
|
$ 228.06 | -1.28 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 3.43 | -4.19 % | $ 7.46 B | NYSE American |  Israel |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
 |
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Anika Therapeutics
ANIK
|
$ 14.51 | 1.04 % | $ 213 M | Nasdaq Global Select Market,SPB | USA |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 6.39 | -3.62 % | $ 175 M | Nasdaq Global Market,SPB | Israel |
 |
BioNTech SE
BNTX
|
$ 94.86 | 4.77 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
 |
Burford Capital Limited
BUR
|
$ 8.28 | 2.86 % | $ 1.34 B | NYSE | Britain |
 |
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | USA |
 |
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | USA |
 |
Actinium Pharmaceuticals
ATNM
|
$ 1.14 | 2.7 % | $ 34.3 M | NYSE American | USA |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.51 | - | $ 385 M | Nasdaq Global Select Market | Britain |
 |
AVEO Pharmaceuticals
AVEO
|
- | - | $ 521 M | Nasdaq Capital Market | USA |
 |
Atea Pharmaceuticals
AVIR
|
$ 6.13 | 1.32 % | $ 500 M | Nasdaq Global Select Market | USA |
 |
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | USA |
 |
Equillium
EQ
|
$ 2.15 | -7.33 % | $ 74.7 M | Nasdaq Global Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.